TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02187744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere®
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paraplatin®
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab-EU
Description: Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere®
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paraplatin®
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study: NCT02358681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac, intranasal
Description: Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, intravenous
Description: Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, intravenous
Description: Placebo of equal volume to IV ketorolac, to be administered by intravenous route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, intranasal
Description: Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
Study: NCT02067130

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fibroscan
Description: Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
Study: NCT00169793

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of kidney stone risk after bariatric surgery
Description: 24 hour urine collections done pre and post surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate risk of kidney stones after bariatric surgery
Description: 24 hour urine collections are done before and after surgery
Study: NCT03244605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
Study: NCT00855673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Mechanical Compression
Description: FM220 device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard medical treatment
Study: NCT06081712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198 Placebo
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198 Placebo
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198 Placebo
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Study: NCT02741856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: For more information please see the arm descriptions section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: For more information please see the arm descriptions section.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: For more information please see the arm descriptions section.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: For more information please see the arm descriptions section.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: For more information please see the arm descriptions section.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: For more information please see the arm descriptions section.
Study: NCT00285233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic islets of Langerhans transplant
Description: Allogeneic islets of Langerhans transplant
Study: NCT04548583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03726944

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm App Meditation
Description: The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm App Meditation
Description: The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm App Meditation
Description: The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unnamed Consumer-Based App Meditation
Description: The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unnamed Consumer-Based App Meditation
Description: The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unnamed Consumer-Based App Meditation
Description: The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Control
Description: The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Control
Description: The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
Study: NCT02416570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02236403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1% Metronidazole 1%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None intervention
Description: Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
Study: NCT03351933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin (Human)
Description: A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
Study: NCT02586129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14755
Description: 20/1500mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1500mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg, QD
Study: NCT03766074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03406767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLA:D Canada Program
Description: The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JointEffort Program
Description: The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
Study: NCT03748784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Study: NCT00929591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine-modulating drug therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine-modulating drug therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT01735240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069 15 mg (3x5 mg capsules) single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg (2x200 mg tablets)
Study: NCT01612754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise reduction work place rules
Description: Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Presence of an examiner in the concerned theatre
Description: Research Clerk present in theatre, writes on note pad.
Study: NCT03107611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study: NCT01752270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35 pretreatment
Description: Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35 pretreatment
Study: NCT05586893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy and Electroacupuncture
Description: We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy and Electroacupuncture
Description: We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher.
Study: NCT03137420

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Scale of Family Distress
Description: Questionnaires at 1, 3, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Scale of Family Distress
Description: Questionnaires at 1, 3, 6 and 12 months
Study: NCT01435603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Advice
Description: Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Advice
Description: Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice Plus Lifestyle Intervention
Description: Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
Study: NCT03219138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography
Description: Use of an uncalibrated acceleromyography
Study: NCT01196507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
Study: NCT01784445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure